Literature DB >> 9574563

Regulation of human mast cell beta-tryptase: conversion of inactive monomer to active tetramer at acid pH.

S Ren1, K Sakai, L B Schwartz.   

Abstract

At neutral pH, human mast cell beta-tryptase is stabilized in its enzymatically active, tetrameric form by heparin, and resists inhibition by biologic protease inhibitors. After dissociation of beta-tryptase from heparin, active tetramers rapidly convert to inactive monomers in an isotonic, neutral pH environment. Although reversible transition states probably exist during this conversion, once inactive monomers form, addition of heparin fails to reconstitute active tetramer at neutral pH. The current study shows that complete reactivation of inactive monomers can occur at acidic pH in a heparin-independent manner. The respective rate-determining steps for formation of tetramer and active enzyme from inactive monomers exhibit second and first order kinetics based on an analysis of initial reaction rates. The optimal pH for tetramer formation and reactivation is about 6, suggesting His residues play a critical role. The optimal ionic strength equivalent is 160 mM NaCl; and the optimal temperature range is 22 degrees C to 37 degrees C. We propose a sequential three-step reactivation process at acidic pH, dimerization of monomers (rate-determining second order step), rapid formation of inactive tetramers, and slow formation of active tetramers (overall rate-determining first order step). Whether reactivation of human beta-tryptase occurs at extracellular or intracellular sites, where the pH is acidic in vivo, should be considered.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9574563

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  The structure of the human betaII-tryptase tetramer: fo(u)r better or worse.

Authors:  C P Sommerhoff; W Bode; P J Pereira; M T Stubbs; J Stürzebecher; G P Piechottka; G Matschiner; A Bergner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Formation of active monomers from tetrameric human beta-tryptase.

Authors:  Ignacio Fajardo; Gunnar Pejler
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

3.  The B12 anti-tryptase monoclonal antibody disrupts the tetrameric structure of heparin-stabilized beta-tryptase to form monomers that are inactive at neutral pH and active at acidic pH.

Authors:  Yoshihiro Fukuoka; Lawrence B Schwartz
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

Review 4.  Mast cell proteoglycans.

Authors:  Elin Rönnberg; Fabio R Melo; Gunnar Pejler
Journal:  J Histochem Cytochem       Date:  2012-08-16       Impact factor: 2.479

5.  Promiscuous processing of human alphabeta-protryptases by cathepsins L, B, and C.

Authors:  Quang T Le; Hae-Ki Min; Han-Zhang Xia; Yoshihiro Fukuoka; Nobuhiko Katunuma; Lawrence B Schwartz
Journal:  J Immunol       Date:  2011-05-11       Impact factor: 5.422

6.  Role of mast cells in male chronic pelvic pain.

Authors:  Joseph D Done; Charles N Rudick; Marsha L Quick; Anthony J Schaeffer; Praveen Thumbikat
Journal:  J Urol       Date:  2012-02-17       Impact factor: 7.450

7.  Dual functionality of β-tryptase protomers as both proteases and cofactors in the active tetramer.

Authors:  Henry R Maun; Peter S Liu; Yvonne Franke; Charles Eigenbrot; William F Forrest; Lawrence B Schwartz; Robert A Lazarus
Journal:  J Biol Chem       Date:  2018-04-16       Impact factor: 5.157

Review 8.  Active monomers of human beta-tryptase have expanded substrate specificities.

Authors:  Yoshihiro Fukuoka; Lawrence B Schwartz
Journal:  Int Immunopharmacol       Date:  2007-07-27       Impact factor: 4.932

Review 9.  The Influence of Early Life Experience on Visceral Pain.

Authors:  Isabella M Fuentes; Julie A Christianson
Journal:  Front Syst Neurosci       Date:  2018-01-26

10.  Impact of naturally forming human α/β-tryptase heterotetramers in the pathogenesis of hereditary α-tryptasemia.

Authors:  Quang T Le; Jonathan J Lyons; Andrea N Naranjo; Ana Olivera; Robert A Lazarus; Dean D Metcalfe; Joshua D Milner; Lawrence B Schwartz
Journal:  J Exp Med       Date:  2019-07-23       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.